Press Releases
  Date Title View
Jan 4, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 34th Annual J. P. Morgan Healthcare...
PDF
Dec 2, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that David Johnston, Executive Vice President and Chief Financial Officer, will present at the upcoming...
PDF
Dec 1, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of new preclinical data with the Company's experimental therapies IMGN529 ...
PDF
Nov 13, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this r...
PDF
Nov 8, 2015
Objective response on mirvetuximab soravtansine in nine of ten (90%) patients with high amounts of target on cancer cells; majority of these responders remained on treatment for at least 24 weeks Most patients with ovarian cancer found to have high or medium expression of target ...
PDF
Oct 27, 2015
− Conference Call Today at 8:00 am ET − Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor α (FRα)-targeting antibody-drug conjugate (ADC); data to be reported at ...
PDF
Oct 13, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss I...
PDF
Sep 17, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Compa...
PDF
Sep 10, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference. ImmunoGen President an...
PDF
Aug 20, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Compa...
PDF
Aug 10, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Canaccord Genuity 35th Annual Growth Conference. ImmunoGen...
PDF
Jul 31, 2015
− Company Provides Corporate Update and Fiscal Year 2016 Financial Guidance − − Conference Call Today at 8:00 am ET − ImmunoGen's wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for ...
PDF
Jul 15, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2015, to disc...
PDF
Jun 17, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first presentation of findings with the Company's CD37-targeting ADC, IMGN529, in combination wi...
PDF
May 30, 2015
Objective response rate (ORR) of 53% - as single agent - in patients with folate-receptor alpha (FRα)-positive platinum-resistant ovarian cancer. Majority of responses are ongoing. Clinical development program advancing, expanding. WALTHAM, Mass.--(BUSINESS WIRE)-- ...
PDF
May 13, 2015
Presentations to include initial findings with Company's mirvetuximab soravtansine (IMGN853) for ovarian cancer and results from Roche's MARIANNE trial with Kadcyla® WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel ...
PDF
May 4, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast...
PDF
Apr 24, 2015
− Conference Call Today at 8:00 am ET− The Company is investing in its wholly owned product programs, including expanding its mirvetuximab soravtansine (IMGN853) and IMGN529 clinical programs and developing plans for recently reacquired coltuximab ravtansine (SAR3419)...
PDF
Apr 9, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 24, 2015, to discuss Immu...
PDF
Apr 1, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. Dr. Berkenbl...
PDF
FirstPrevious
3
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue